- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03017573
Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
April 10, 2024 updated by: Institut Curie
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer and Cervical cancer patients.
This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors.
All patients will receive standard treatment according to the stage of the diseases and usual procédures.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Patients will have blood and +/- tumor samples at the following times :
if eligible for surgery :
- at surgery (blood + tumor and nodes)
- after surgery (blood)
- 6 months after surgery if non recurrence (Blood)
- before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes if possible)
- before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
- at progression (blood + tumor biopsie and nodes if possible)
if eligible for neoadjuvant chemotherapy :
- before neoadjuvant therapy (blood + tumor biopsie and nodes)
- during neoadjuvant therapy (post cycle 1) (blood)
- at the time of surgery (blood + tumor and nodes)
- 6 months after surgery if non recurrence (Blood)
- before cycle 1 of adjuvant chemotherapy or before radiotherapy (blood + tumor biopsie and nodes)
- before cycle 2 of adjuvant chemotherapy or after radiotherapy (blood)
- at progression (blood + tumor biopsie and nodes)
Study Type
Interventional
Enrollment (Estimated)
700
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne-Sophie PLISSONNIER
- Phone Number: 01 47 11 23 78
- Email: drci.promotion@curie.fr
Study Locations
-
-
-
Bordeaux, France, 33076
- Not yet recruiting
- Institut Bergonié
-
Contact:
- Adeline PETIT, MD
- Email: A.Petit@.bordeaux.unicancer.fr
-
Principal Investigator:
- Adeline PETIT, MD
-
Lille, France, 59000
- Recruiting
- Centre Oscar Lambret
-
Contact:
- Camille PASQUESOONE, MD
- Email: c.pasquesoone@o-lambret.fr
-
Principal Investigator:
- Camille PASQUESOONE, MD
-
Lyon, France, 69373
- Not yet recruiting
- Centre Leon Berard
-
Contact:
- Nicolas CHOPIN, MD
-
Contact:
-
Principal Investigator:
- Nicolas CHOPIN, MD
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- Christophe LE TOURNEAU, MD
- Email: christophe.letourneau@curie.fr
-
Principal Investigator:
- Christophe LE TOURNEAU, MD
-
Saint-cloud, France, 92210
- Recruiting
- Institut Curie Hopital Rene Huguenin
-
Contact:
- Nicolas POUGET, MD
- Email: nicolas.pouget@curie.fr
-
Principal Investigator:
- Nicolas POUGET, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Tumor types :
- Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy
- Newly diagnosed treatment-naïve head and neck cancer patients eligible for surgery
- Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1 with nodal metastasis, postoperative positive margin or parametrial-vaginal involvement, and (2) stage ≥IIa2).
- Male or female patients ≥ 18 years of age
- Signed informed consent
Exclusion Criteria:
- Male or female patients ≤18 years old
- Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Individually deprived of liberty or placed under the authority of a tutor
- Patients not affiliated to the Social Security System
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tumor and blood sampling
Patients will have a biopsy or a surgery and blood sampling at different time points.
|
Tumoral tissues samples must be collected at different times points :
OR
Blood samples must be collected at different times points :
OR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation between tumor molecular/immunological profile and Baseline clinicobiological features
Time Frame: up to 6 months
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation between disease recurrence and molecular and/or immunological biomarkers
Time Frame: up to 24 months
|
up to 24 months
|
Correlation between genomic alterations and immune parameters
Time Frame: up to 24 months
|
up to 24 months
|
Correlation between mutations load and immune parameters
Time Frame: up to 24 months
|
up to 24 months
|
Correlation between ctDNA levels, de novo mutations in ctDNA and immune
Time Frame: up to 24 months
|
up to 24 months
|
For cervical cancer patient, correlation between ctDNA levels and kinetics, and prognosis, prediction of recurrence
Time Frame: up to 24 months
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christophe LE TOURNEAU, Prof., Institut Curie
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2017
Primary Completion (Estimated)
August 1, 2028
Study Completion (Estimated)
January 6, 2031
Study Registration Dates
First Submitted
January 9, 2017
First Submitted That Met QC Criteria
January 9, 2017
First Posted (Estimated)
January 11, 2017
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 10, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Breast Diseases
- Breast Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Triple Negative Breast Neoplasms
Other Study ID Numbers
- IC 2016-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Sponsor will share de-identified data sets.
Documents generated under the project will be disseminated in accordance with Institut Curie policies.
IPD Sharing Time Frame
Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.
IPD Sharing Access Criteria
Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Tumor biopsies / Tumor surgery
-
M.D. Anderson Cancer CenterCompleted
-
National University Hospital, SingaporeUnknownNasopharyngeal Cancer | Colorectal CancerSingapore
-
Institut CurieCompletedCervical CancerFrance, Germany, Netherlands, Romania, Serbia
-
Medical University of GrazRecruitingMultiple Stereotactic Tumor Biopsies During a Brain Tumor ResectionAustria
-
The Netherlands Cancer InstituteMerck Sharp & Dohme LLC; Roche Pharma AG; AstraZenecaUnknown
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingGlioma | Glioblastoma | Glioma Glioblastoma MultiformeItaly
-
National University Hospital, SingaporeUnknownAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With ImatinibSingapore
-
Hospital Sirio-LibanesActive, not recruiting
-
Jules Bordet InstituteCompletedInvasive Breast CancerBelgium
-
Centre Jean PerrinCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerFrance